US scientists reclassify diffuse large B-cell lymphoma April 16, 2018 Source: Xinhuanet In a recent report, US researchers said they reclassified a common malignant lymphoma at the molecular level, and the new classification is expected to help prognosis and personalized treatment of the disease. Researchers at the National Institutes of Health Cancer Research Center divided diffuse large B-cell lymphoma (DLBCL) into four types according to genotyping, partly explaining why a certain treatment is effective for some patients and not for another. . They reported this in the latest issue of the New England Journal of Medicine. Previously, diffuse large B-cell lymphoma was classified as "activated B-cell-like" and "centralized center B-cell-like", with the former having an average survival rate of 40% and the latter having an average survival rate of 75%. However, it often recurs after treatment. The researchers performed genetic variation and gene expression analysis on 574 tumor samples. The results confirmed that BN2 and EZB have good genotyping effects and poor genotyping of MCD and N1. The researchers found that four genotypes were found in the past two categories of diffuse large B-cell lymphoma. Research director Louis Stodd explained that tumors may be both a pro-prognosis "activated B-cell-like" and BN2 genotyping, which can significantly improve chemotherapy. Diffuse large B-cell lymphoma is a clinically common subtype of malignant lymphoma. Because this is a group of malignant tumors that differ greatly in clinical manifestations, histomorphology, and prognosis, accurate risk stratification of patients is important to improve cure rates. (Reporter Zhou Zhou) Lactobacillus Reuteri,Lactobacillus Reuteri Probiotic,Lactobacillus Reuteri Products,Lactobacillus Reuteri Supplements Biodep Biotechnology Co. ,Ltd. , https://www.mbioda.com
US scientists reclassify diffuse large B-cell lymphoma
Next Article
Winter greenhouse vegetables fill light